<DOC>
	<DOCNO>NCT01057264</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Abraxane速 ( nab-paclitaxel ) give directly liver , combination Gemzar速 ( gemcitabine ) Avastin速 ( bevacizumab ) give vein .</brief_summary>
	<brief_title>HAI Abraxane With Gemcitabine Bevacizumab</brief_title>
	<detailed_description>The Study Drugs : Nab-paclitaxel design block cancer cell divide , may cause cancer cell die . Gemcitabine design disrupt growth cancer cell , may cause cancer cell die . Bevacizumab design block growth blood vessel supply nutrient need tumor growth , may prevent slow growth cancer cell . Bevacizumab long FDA approve treat breast cancer . Study Groups : If find eligible take part study , assign dose level combination nab-paclitaxel gemcitabine base join study . Up 6 dose level nab-paclitaxel gemcitabine test . All participant receive dose level bevacizumab , regardless join study . Between 3-6 participant enrol dose level . The first group participant receive low dose level combination nab-paclitaxel gemcitabine combination bevacizumab . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose combination nab-paclitaxel gemcitabine give combination bevacizumab find . Once high tolerable dose find , 12 additional participant receive dose . This called expansion group . Catheter Placement : On Day 1 21-day study cycle , catheter ( sterile , flexible tube ) place large artery carry blood liver groin area , right side body . The area catheter place first numbed local anesthetic . The catheter tap place prevent move come receive nab-paclitaxel . You lie flat back receive study drug , bedrest catheter remove . The doctor performs catheter placement procedure explain detail , ask sign separate consent form describe catheter placement procedure risk detail . After catheter place , receive heparin , drug use help prevent blood clot . Heparin start soon catheter place continue 2 hour . The catheter remove right receive nab-paclitaxel . While catheter remove , study staff apply pressure groin area 15 minute order stop bleeding . The catheter place 1 hour , nab-paclitaxel administration complete . Study Drug Administration : Nab-paclitaxel give catheter artery carry blood liver nonstop 1 hour start Day 1 cycle . If study doctor think need , give drug vein low risk nausea dose part standard , routine care . Gemcitabine give vein 1 hour Days 1 8 cycle . Bevacizumab give vein Day 1 cycle . The first time receive bevacizumab , give 90 minute . If tolerate well , rest dos give 30-60 minute . If tolerate study drug combination well , dos receive may lower . If experience certain side effect , study drug dos may delay study cycle may last long 21 day . Starting least 24 hour receive study drug Day 1 , receive Neupogen速 ( filgrastim ) needle injected skin . You continue receive filgrastim 3 day ( Days 2-4 ) . Filgrastim give help prevent possible side effect relate study drug . Study Visits : You stay hospital 7 day ( Days 1-7 cycle ) begin cycle , recover side effect may experience . You see doctor `` advanced practice '' nurse every day hospital check recover . On Day 1 cycle : - You physical exam , include measurement weight vital sign . - Blood ( 3 teaspoon ) draw routine test , test blood 's ability clot , tumor marker test . On Day 2 cycle : -You physical exam , include measurement weight vital sign . Every 2 cycle , time study doctor think need , woman able become pregnant urine pregnancy test . To remain study , pregnancy test must negative . At end every 2 cycle ( Cycles 2 , 4 , 6 , ) , time study doctor think need , chest x-ray , CT scan , MRI scan , PET scan and/or PET/CT scan perform check status disease . After 10 cycle study drug treatment , may scan every 3 cycle instead 2 cycle , doctor feel best interest . If study doctor think well , type scan list may perform . Follow-Up Visit : Six ( 6 ) week last dose study drug combination , stop take study drug combination reason , follow test procedure perform : - You physical exam . - Your performance status record . - Blood ( 2 teaspoon ) draw routine test test blood 's ability clot . - If study doctor think need , chest x-ray , CT scan , MRI scan , PET scan and/or PET/CT scan perform check status disease . If study doctor think well , type scan list may perform . Length Study : You may continue take study drug combination long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur . This investigational study . Nab-paclitaxel FDA approve commercially available give vein treatment breast cancer . Gemcitabine FDA approve commercially available treatment pancreatic cancer , breast cancer metastatic ( spread part body ) , non-small cell lung cancer ( NSCL ) , ovarian cancer . Bevacizumab FDA approve commercially available treatment metastatic colorectal cancer , NSCL , type brain cancer call glioblastoma multiforme . Giving nab-paclitaxel artery carry blood directly liver investigational . Using study drug combination treat advanced cancer spread liver investigational . Up 80 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients must histologically confirm cancer metastatic liver metastasis . 2 . Patients refractory standard therapy , relapse standard therapy , standard therapy increase survival least 3 month , unless drug protocol regimen part standard care . 3 . Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 ( capable self care unable carry work activity ) . 4 . Adequate renal function ( serum creatinine &lt; /= 2.0 mg/dL calculate glomerular filtration rate ( GFR ) &gt; /= 40 mL/min creatinine &gt; 2.0 mg/dL ) . 5 . Hepatic function : Total bilirubin &lt; /= 5 mg/dL , alanine transaminase ( ALT ) &lt; /= 5 time upper normal reference value . 6 . Adequate bone marrow function ( absolute neutrophil count ( ANC ) &gt; /= 1500 cells/uL ; platelet ( PLT ) &gt; /= 100,000 cells/uL ) . 7 . At least three week previous cytotoxic chemotherapy day 1 hepatic arterial infusion ( HAI ) infusion . After targeted biologic therapy 5 halflives three week , whichever short . 8 . All female childbearing age MUST negative urine human chorionic gonadotropin ( HCG ) test unless prior hysterectomy menopause ( define age 55 six month without menstrual activity ) . Patients become pregnant breastfeed study . Sexually active patient use effective birth control . 9 . Must &gt; /= 18 year age . 1 . Pregnant female . 2 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 3 . Serious nonhealing wound , ulcer bone fracture . 4 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day . 5 . Uncontrolled systemic vascular hypertension ( systolic blood pressure &gt; 140 mm Hg , diastolic blood pressure &gt; 90 mm Hg ) . 6 . Uncontrolled intercurrent illness , include , limited , ongoing active infection require parental antibiotic , psychiatric illness/social situation would limit compliance study requirement . 7 . Patients already uncompensated liver failure ( i.e . Child Pugh Liver Classification C ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Liver</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hepatic arterial infusion</keyword>
	<keyword>HAI</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Neupogen</keyword>
</DOC>